Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (5y) (2015 - 2026)
Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.20% |
| Mar 31, 2026 | 42.40% |
| Dec 31, 2025 | -15.87% |
| Sep 30, 2025 | 39.65% |
| Jun 30, 2025 | 5.60% |
| Mar 31, 2025 | -27.53% |
| Dec 31, 2024 | 22.85% |
| Sep 30, 2024 | 17.32% |
| Jun 30, 2024 | 2.94% |
| Mar 31, 2024 | 18.87% |
| Dec 31, 2023 | 49.36% |
| Sep 30, 2023 | 9.40% |
| Jun 30, 2023 | 75.23% |
| Mar 31, 2023 | -11.05% |
| Dec 31, 2022 | 50.40% |
| Sep 30, 2022 | 42.47% |
| Jun 30, 2022 | 25.55% |
| Mar 31, 2022 | 16.62% |
| Dec 31, 2021 | 30.80% |
| Sep 30, 2021 | 20.15% |